Pfizer v. Sandoz: Inlyta® Axitinib Patent Dispute Dismissed Without Prejudice
Pfizer Inc. and PF Prism IMB B.V. filed suit against Sandoz Inc. in the District of Delaware asserting US8791140B2 — covering axitinib, the active ingredient in Pfizer’s oncology drug Inlyta® — against Sandoz’s generic tablet application. After 218 days, the parties jointly stipulated to dismiss the case without prejudice, with each side bearing its own costs, leaving the door open for future litigation.
Pfizer’s Inlyta® ANDA suit against Sandoz ends with no merits ruling
On 12 November 2024, Pfizer Inc. and co-plaintiff PF Prism IMB B.V. filed a Hatch-Waxman infringement action against Sandoz Inc. in the District of Delaware (Case No. 1:24-cv-01244), asserting US Patent No. 8,791,140 against Sandoz’s abbreviated new drug application (ANDA) seeking approval for generic axitinib tablets at 1 mg and 5 mg doses — the reference-listed drug being Pfizer’s Inlyta®, a tyrosine kinase inhibitor used in advanced renal cell carcinoma.
The case closed on 18 June 2025 — 218 days after filing — via a stipulated dismissal without prejudice signed under Federal Rules of Civil Procedure 41(a)(1) and 41(c). No damages were awarded, no injunction was issued, and no merits determination was reached. Critically, ‘without prejudice’ preserves Pfizer’s right to refile the same claims against Sandoz, meaning the underlying patent dispute is legally unresolved.
A 218-day resolution in ANDA litigation — before even a Markman hearing in most schedules — suggests the parties likely reached an accommodation outside of court, possibly including a negotiated entry date for Sandoz’s generic, a licensing arrangement, or a strategic decision tied to Inlyta®’s commercial lifecycle. The public record does not disclose settlement terms, making the commercial implications impossible to confirm from docket data alone.
Filing to Dismissed without Prejudice in 218 days
218 days — resolved before trial, suggesting early negotiation or regulatory recalculation
Dismissed without prejudice: what the stipulated exit means for both sides
Rules 41(a)(1) & 41(c): a consensual, no-merits exit
A dismissal under Rule 41(a)(1) is a plaintiff-initiated voluntary dismissal requiring no court order when filed as a stipulation signed by all parties. Rule 41(c) extends this to counterclaims. Crucially, ‘without prejudice’ means no adjudication on the merits occurred — the patent’s validity and infringement were never ruled upon. Pfizer retains the legal right to refile the same infringement claims against Sandoz at a future date.
No merits rulingPfizer’s ‘140 patent remains unchallenged in this proceeding
Because the case was dismissed without prejudice, US8791140B2 has not been ruled invalid, unenforceable, or non-infringed in this action. Pfizer preserves its full enforcement posture. However, the dismissal also signals Pfizer chose not to press litigation to judgment — potentially reflecting a licensing deal, agreed generic entry date, or reduced commercial urgency for Inlyta® given its market maturity. The patent’s enforceability remains intact but untested here.
Patent survives unchallengedSandoz avoids adverse ruling — but faces re-litigation risk
Sandoz obtained a clean exit from this litigation without a finding of infringement or validity of the ‘140 patent. With no injunction and no damages award, Sandoz’s ANDA progress is not legally blocked by this dismissal. However, the ‘without prejudice’ status means Pfizer could refile if Sandoz’s ANDA advances toward FDA approval on terms Pfizer finds commercially unacceptable. Sandoz’s freedom to market hinges on any private agreement reached between the parties.
Re-litigation risk persistsInlyta® generic entry timeline remains commercially uncertain
Axitinib is an established oncology asset; Inlyta® faces a maturing brand lifecycle as competition grows. A without-prejudice dismissal at this stage — before claim construction — is consistent with a negotiated authorised generic arrangement or a stipulated entry date commonly seen in ANDA settlements. Competitors and payers monitoring generic axitinib availability should note that the public record provides no confirmed timeline. Broader oncology VEGFR-inhibitor IP watchers should track Pfizer’s refilings.
Entry date unconfirmedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Pfizer, Inc. | Company | Pfizer Inc. — global pharmaceutical innovator; holder of US8791140B2 (axitinib/Inlyta®)Search in Eureka ↗ |
| Co-Plaintiff | PF Prism Ibm C.V. | Individual | Search in Eureka ↗ |
| Defendant | Sandoz, Inc. | Company | Sandoz Inc. — generic pharmaceutical manufacturer; ANDA filer for generic axitinib tabletsSearch in Eureka ↗ |
| Plaintiff counsel | Megan Elizabeth Dellinger | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Pfizer, Inc.Search in Eureka ↗ |
| Defendant counsel | Dominick T. Gattuso | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Judy He | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Laura A. Lydigsen | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Mark H. Remus | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant law firm | Heyman Enerio Gattuso & Hirzel, LLP | Law Firm | Representing Sandoz, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Jennifer L. Hall | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated dismissal is phrased as a mutual agreement under Rules 41(a)(1) and 41(c), with no admission of liability and no merits determination by the court. The phrase ‘without prejudice’ is legally operative: it preserves Pfizer’s ability to refile identical claims against Sandoz, distinguishing this outcome from a with-prejudice dismissal that would extinguish those rights. The cost neutrality — ‘all parties shall bear their own costs’ — is consistent with a negotiated resolution rather than a default or abandonment, suggesting both sides found value in exiting litigation at this stage.
US8791140B2 — Axitinib compound patent underlying Pfizer’s Inlyta®
US8791140B2 (application no. US12/594,575) is a U.S. patent covering axitinib — a selective tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR-1, -2, and -3). The patent underpins Pfizer’s branded oncology drug Inlyta®, approved by the FDA for the treatment of advanced renal cell carcinoma. As a compound-level or formulation patent asserted via the Hatch-Waxman pathway, it forms a primary barrier to generic axitinib entry in the U.S. market.
For pharmaceutical competitors and ANDA filers, US8791140B2 represents a critical blocking asset in the axitinib commercial space. Pfizer’s decision to file suit immediately upon Sandoz’s ANDA certification is standard Hatch-Waxman practice, triggering the 30-month stay of FDA approval. Because no court has ruled on validity or infringement of this patent in this case, competitors cannot benchmark the ‘140 patent’s enforceability from the public record. Any company developing axitinib generics, reformulations, or VEGFR-class follow-ons should treat this patent as live and enforceable until expiry or a definitive invalidity ruling.
Should your team run an FTO analysis against US8791140B2?
Any pharmaceutical or biotech team developing a generic axitinib tablet (1 mg or 5 mg), an axitinib reformulation, a 505(b)(2) product referencing Inlyta®, or a next-generation VEGFR-1/2/3 inhibitor should treat US8791140B2 as an active clearance target. This dismissal without prejudice provides zero merits clearance — Pfizer retains full enforcement rights and has demonstrated willingness to litigate in Delaware. The absence of a Markman record means claim scope is undefined in the case law, increasing uncertainty.
PatSnap Eureka’s FTO Search Agent enables teams to map the full claim scope of US8791140B2, identify prior art cited during prosecution, surface any inter partes review (IPR) petitions filed against this patent, and benchmark against comparable VEGFR inhibitor patents in Pfizer’s portfolio. R&D and regulatory teams can generate an FTO report in a fraction of the time required by manual docket review — helping you make go/no-go ANDA decisions with confidence and speed.
Run a freedom-to-operate analysis on US8791140B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman ANDA cases involving oncology small-molecule patents
Explore related ANDA patent infringement cases in the District of Delaware involving oncology small-molecule drugs and VEGFR inhibitor compound patents.
What this case signals for the ANDA oncology patent IP landscape
Early exits in Hatch-Waxman cases rarely mean the dispute is over — for axitinib, the commercial and IP game is still live.
Without-prejudice ANDA dismissals often mask private entry-date deals
Hatch-Waxman stipulated dismissals without prejudice — particularly before claim construction — are a well-recognised signal that the parties have negotiated a generic entry date or authorised generic arrangement. Pfizer’s decision to walk away at 218 days, bearing its own costs, suggests a commercial accommodation rather than litigation fatigue. IP teams monitoring axitinib market dynamics should track any FDA tentative approval updates for Sandoz’s ANDA.
US8791140B2 remains a live enforcement tool — FTO exposure not cleared
Because no court ruled on validity or infringement, US8791140B2 retains full presumptive validity. Any company with an axitinib ANDA — or a follow-on formulation product — cannot rely on this dismissal as prior art or a merits finding. An independent FTO analysis against the ‘140 patent remains necessary for any generic entrant or biosimilar-adjacent developer working in VEGFR inhibitor chemistry.
Pfizer v Sandoz — key questions answered
A dismissal without prejudice means the court made no ruling on the merits of Pfizer’s infringement claims. US8791140B2 was not found valid, invalid, infringed, or non-infringed. Pfizer retains the legal right to refile the same claims against Sandoz if circumstances change — for example, if Sandoz’s ANDA receives FDA approval without an agreed entry date. The ‘140 patent remains presumptively valid and enforceable.
Pfizer asserted US Patent No. 8,791,140 (application no. US12/594,575), which covers axitinib — the active ingredient in Pfizer’s Inlyta® tablets at 1 mg and 5 mg doses. Axitinib is a selective VEGFR tyrosine kinase inhibitor approved for advanced renal cell carcinoma. The case was a Hatch-Waxman ANDA infringement action filed in the District of Delaware on 12 November 2024.
The public record does not disclose the reason for the early dismissal. However, 218-day resolutions before claim construction in Hatch-Waxman cases are consistent with a negotiated generic entry date, an authorised generic agreement, or a licensing arrangement. The cost-neutral, without-prejudice structure of the dismissal suggests a mutual commercial accommodation rather than litigation failure or patent weakness. No private settlement terms are publicly available.
No. A without-prejudice dismissal with no merits ruling provides zero freedom-to-operate clearance for third parties. US8791140B2 remains presumptively valid. Other ANDA filers for axitinib cannot rely on this case as precedent for invalidity or non-infringement. Independent FTO analysis and patent prosecution history review remain necessary for any company seeking to enter the axitinib generic market.
The case was filed in the United States District Court for the District of Delaware (Case No. 1:24-cv-01244) and assigned to Judge Jennifer L. Hall. Delaware is the predominant venue for Hatch-Waxman ANDA patent litigation in the United States, consistent with Pfizer’s standard enforcement practice. The case was closed on 18 June 2025 via stipulated dismissal without prejudice.
PatSnap Eureka searches patents and litigation data to answer instantly.